CJC–1295 without DAC 5mg

CJC-1295: A Potent Growth Hormone Analog with Performance-Boosting Benefits

CJC-1295 is a synthetic analog of growth hormone that was originally developed for treating medical conditions but has gained popularity as both a research chemical and a performance enhancer due to its powerful effects on the human body. Known as a “cleaner peptide,” CJC-1295 is highly valued for its ability to provide targeted and specific benefits, particularly through the stimulation of growth hormone (GH) secretion. By promoting the release of GH and insulin-like growth factor 1 (IGF-1), CJC-1295 can significantly enhance protein synthesis, speed up recovery, reduce body fat, and boost immune function. These effects make it particularly appealing to athletes looking for an edge and adults seeking an energy boost. Many users report experiencing an almost “fountain of youth” effect due to the peptide’s ability to enhance energy and vitality.

How CJC-1295 Works

CJC-1295 acts on the pituitary gland by binding to the Growth Hormone Releasing Hormone (GHRH) receptors, triggering the brain to release growth hormones. Research has shown that CJC-1295 can increase growth hormone levels by 200-1000% in individuals aged 21-61, with both men and women showing notable increases. The growth hormone released can remain active in the body for 6-8 days, which is a significant advantage over traditional HGH therapies that often have shorter durations and potential side effects. This extended half-life makes CJC-1295 a highly attractive option for those seeking consistent, long-term benefits without the downsides associated with other treatments.

Anti-Aging and Metabolism Benefits

CJC-1295 has also shown promise in improving metabolism and acting as an anti-aging agent, making it particularly popular among individuals in their 30s and beyond. As natural HGH production declines with age, people often experience a loss of muscle mass, reduced strength, difficulty maintaining a healthy weight, slower recovery, and signs of aging. By stimulating growth hormone release, CJC-1295 helps address these issues, supporting muscle growth, fat loss, and overall vitality, giving users a more youthful and energetic feel.

The Development of CJC-1295

CJC-1295 was developed by ConjuChem Biotechnologies, a biotechnology company based in Quebec, Canada. The peptide is a modified version of Sermorelin (GHRH 1-29) with improvements that enhance its stability and effectiveness. Specifically, CJC-1295 incorporates amino acid substitutions (Gln, Ala, Leu, D-Ala) that prevent degradation, resulting in a much longer half-life compared to Sermorelin, which lasts only about 30 minutes. The key to its success lies in isolating the first 29 amino acids of Sermorelin, enabling CJC-1295 to effectively stimulate the pituitary gland to release growth hormone in a pulsed manner, providing a sustained and potent effect.

Key Features of CJC-1295:

• Prevents methionine oxidation
• Increases peptide bioactivity
• Reduces asparagines rearrangement
• Prevents DPP-IV cleavage formation

These modifications enhance the peptide’s effectiveness in stimulating the release of growth hormone, making CJC-1295 a powerful tool for improving muscle growth, fat loss, and recovery.

CJC-1295 With DAC vs. Without DAC

CJC-1295 exists in two forms: with DAC (Drug Affinity Complex) and without DAC. While both versions offer similar benefits, the key difference lies in their half-life and how long the peptide remains active in the body.

• CJC-1295 with DAC:
  DAC is a modification that extends the peptide’s half-life, allowing it to remain active in the body for up to 8 days. This version is often paired with other peptides like Ipamorelin to slow degradation and prolong the peptide’s effects. By gradually releasing growth hormone over a longer period, CJC-1295 with DAC provides a more controlled, sustained effect.
• CJC-1295 without DAC:
  This form of CJC-1295 has a much shorter half-life, typically lasting around 30 minutes. Despite its brief duration, this shorter half-life can actually be beneficial, as it provides quick, pulsing releases of growth hormone without overwhelming the body. This more “natural” release mimics the body’s own growth hormone secretion patterns, making it ideal for those seeking a less intense and more physiologically in-tune effect.

References

1. Next Generation Medicines from Therapeutic Peptides | ConjuChem LLC. Conjuchem.com. (2021). Retrieved 13 March 2021, from http://www.conjuchem.com/.
2. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010 Nov-Dec;2(11-12):647-50. doi: 10.1002/dta.233. Epub 2010 Dec 10. PMID: 21204297.
3. What is Prohibited. World Anti-Doping Agency. (2021). Retrieved 26 February 2021, from https://www.wada-ama.org/en/content/what-is-prohibited/prohibited-at-all-times/peptide-hormones-growth-factors-related-substances-and-mimetics.
4. (2021). Retrieved 26 February 2021, from https://www.sciencedirect.com/science/article/pii/S205005211730032X.
5. Introduction to Bioconjugation. Chemistry LibreTexts. (2021). Retrieved 26 February 2021, from https://chem.libretexts.org/Bookshelves/Organic_Chemistry/Supplemental_Modules_
   (Organic_Chemistry)/Reactions/Introduction_to_Bioconjugation.
6. CJC1295 Without DAC. Pubchem.ncbi.nlm.nih.gov. (2021). Retrieved 26 February 2021, from https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC#section=Biologic-Description.
7. Albumin_Bioconjugates_Activate_the_GRF_Receptor_on_the_Anterior_Pituitary_in_
   Rats_Identification_of_CJC-1295_as_a_Long_Lasting_GRF_Analog. (2021). Retrieved 26 February 2021, from https://www.researchgate.net/publication/228484039_hGRF1-29-.
8. Perras, B., Marshall, L., Köhler, G., Born, J., & Fehm, H. L. (1999). Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology, 24(7), 743–757. https://doi.org/10.1016/s0306-4530(99)00027-x
9. Chennaoui M, Vanneau T, Trignol A, Arnal P, Gomez-Merino D, Baudot C, Perez J, Pochettino S, Eirale C, Chalabi H. How does sleep help recovery from exercise-induced muscle injuries? J Sci Med Sport. 2021 Oct;24(10):982-987. doi: 10.1016/j.jsams.2021.05.007. Epub 2021 May 18. PMID: 34074604.
10. Schüssler, P., Yassouridis, A., Uhr, M., Kluge, M., Weikel, J., Holsboer, F., & Steiger, A. (2006). Growth hormone-releasing hormone and corticotropin-releasing hormone enhance non-rapid-eye-movement sleep after sleep deprivation. American journal of physiology. Endocrinology and metabolism, 291(3), E549–E556. https://doi.org/10.1152/ajpendo.00641.2005
11. Velloso C. P. (2008). Regulation of muscle mass by growth hormone and IGF-I. British journal of pharmacology, 154(3), 557–568. https://doi.org/10.1038/bjp.2008.153
12. (2021). Retrieved 26 February 2021, from https://academic.oup.com/jcem/article/89/9/4445/2844545.
13. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse | American Journal of Physiology-Endocrinology and Metabolism. Journals.physiology.org. (2021). Retrieved 26 February 2021, from https://journals.physiology.org/doi/full/10.1152/ajpendo.00201.2006.
14. Lipodystrophy study halted after patient death. (2022). Retrieved 14 June 2022, from https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death
15. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Taylor & Francis. (2021). Retrieved 26 February 2021, from https://www.tandfonline.com/doi/abs/10.3109/10826084.2015.1082595?journalCode=isum20.
16. Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman, Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults, The Journal of Clinical Endocrinology & Metabolism, Volume 91, Issue 3, 1 March 2006, Pages 799–805, https://doi.org/10.1210/jc.2005-1536
17. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults, J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.